Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Muscle Nerve. 2018 Dec 26;59(3):303–308. doi: 10.1002/mus.26385

Figure 1. CONSORT diagram: participant enrollment and follow-up for the trial.

Figure 1.

Twenty-four volunteers with ALS were assessed for eligibility. Eighteen enrolled in the trial but two were never dosed as they withdrew consent between Screening and Baseline due to unrelated medical problems. The remaining 16 participants received RNS60 and contributed data.